NCT04169321View on ClinicalTrials.gov

Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

March 30, 2025

Study Completion Date

June 9, 2025

Conditions
Solid Tumor, Unspecified, AdultLymphoma
Interventions
DRUG

Single Arm

\[68Ga\]-NOTA-hGZP is a PET imaging agent.

Trial Locations (3)

333

Chang-Gung Memorial Hospital, Taoyuan

35294

University of Alabama at Birmingham, Birmingham

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

University of Alabama at Birmingham

OTHER

collaborator

Chang Gung Memorial Hospital

OTHER

lead

Cytosite Biopharma Inc.

INDUSTRY

NCT04169321 - Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors | Biotech Hunter | Biotech Hunter